In a long-term prospective study following 5,626 patients with rheumatoid arthritis for 25 years, methotrexate use was associated with a substantial reduction in risk of death, after adjustment for individual propensity for methotrexate use (adjusted HR 0.30; 95% CI 0.09–1.03). The reduction in mortality risk was evident only in those who used the therapy for >1 year, but higher cumulative exposure did not translate into increased survival.
ORIGINAL RESEARCH PAPER
Wasko, M. C. et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.37723
Rights and permissions
About this article
Cite this article
Methotrexate therapy confers survival advantage. Nat Rev Rheumatol 8, 692 (2012). https://doi.org/10.1038/nrrheum.2012.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.194